KPL

What Kwality Pharmaceuticals promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 19 tracked 0 delivered 1 missed 18 open
  • Q1 FY27 Revenue went quiet said Q4 FY26 Promised: ₹150 crores to ₹160 crores Q1 FY27: The Q1 FY27 earnings summary did not provide the actual consolidated revenue figure for the quarter, making it impossible to verify if the guided range of ₹150-160 crores was met.
  • FY27 Revenue revised up said Q4 FY26 Promised: ₹650 crores Q1 FY27: Management revised the FY27 revenue guidance upwards to 'plus INR700 crores', citing strong performance expectations and new registrations.
  • FY27 PAT on track said Q4 FY26 Promised: ₹100 crores Q1 FY27: Management revised FY27 revenue guidance upwards to over ₹700 crores while maintaining the EBITDA margin guidance of 26-27%. While a new PAT target was not explicitly stated, the higher revenue base suggests the ₹100 crore PAT target remains achievable.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 19 tracked commitments for Kwality Pharmaceuticals — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens